REVERBERANT SHEAR WAVE FIELD ESTIMATION OF BODY PROPERTIES

    公开(公告)号:US20200054217A1

    公开(公告)日:2020-02-20

    申请号:US16346327

    申请日:2017-11-03

    Inventor: Kevin PARKER

    Abstract: A reverberant shear wave field in an object such as a patient's body or organ causes deformations in one or more selected directions measured with an imaging modality such as ultrasound or MR equipment or other imaging equipment, to estimate displacements in one or more selected directions over time increments and then viscoelastic properties such as stiffness or other parameters of the ROI.

    Artemisinin derivatives, methods for their preparation and their use as antimalarial agents

    公开(公告)号:US10544159B2

    公开(公告)日:2020-01-28

    申请号:US15492180

    申请日:2017-04-20

    Abstract: Derivatives of the antimalarial agent artemisinin, compositions comprising the derivatives, methods for preparing the derivatives, and their uses in pharmaceutical compositions intended for the treatment of parasitic infections are provided. Methods are provided for the production of artemisinin derivatives via functionalization of positions C7 and C6a, and optionally, in conjunction with modifications at positions C10 and C9, via chemoenzymatic methods. Recombinant cytochrome P450 polypeptides are also provided for use in the methods. The artemisinin derivatives can be used for the treatment of malaria and other parasitic infections, alone or in combination with other antiparasitic drugs.

    Induced pluripotent cell-derived oligodendrocyte progenitor cells for the treatment of myelin disorders

    公开(公告)号:US10450546B2

    公开(公告)日:2019-10-22

    申请号:US14764507

    申请日:2014-02-06

    Abstract: The present disclosure relates to a preparation of CD140a/PDGFRα positive cells that comprises oligodendrocyte progenitor cells co-expressing OLIG2 and CD140a/PDGFRα. The preparation of cells is derived from pluripotent cells that were derived from skin cells, fibroblasts, umbilical cord blood, peripheral blood, bone marrow, or other somatic cells. The cell preparation has an in vivo myelination efficiency that is equal to or greater than the in vivo myelination efficiency of a preparation of A2B5+/PSA-NCAM−sorted fetal human tissue derived oligodendrocyte progenitor cells. Methods of making, isolating and using the disclosed cell preparation are also described.

Patent Agency Ranking